Neoadjuvant Immunotherapy for Locally Advanced Melanoma

Area of Science:

• Oncology
• Immunotherapy
• Melanoma Research

Background:

• Clinical stage III melanoma carries a poor prognosis despite current adjuvant therapies.
• Neoadjuvant therapy (preoperative systemic treatment) is a promising paradigm for improving outcomes in melanoma.
• It allows for earlier disease intervention and potential reduction in surgical complications.

Purpose of the Study:

• To evaluate the efficacy and safety of neoadjuvant immunotherapy for clinical stage III melanoma.
• To assess the correlation between pathologic complete response (pCR) and patient outcomes.
• To identify optimal neoadjuvant immunotherapy regimens and understand their translational effects.

Main Methods:

• Review of early phase clinical trials investigating neoadjuvant immunotherapy (ipilimumab, nivolumab, pembrolizumab).
• Meta-analysis of relapse-free survival rates and pooled data analysis for pCR correlation.
• Translational studies examining T cell responses in the tumor microenvironment and peripheral blood.

Main Results:

• Neoadjuvant immunotherapy demonstrates high rates of pathologic complete response (pCR).
• A meta-analysis shows over 80% 1-year relapse-free survival with neoadjuvant immunotherapy.
• pCR is strongly correlated with improved patient outcomes, and specific dosing regimens (e.g., ipilimumab 1 mg/kg + nivolumab 3 mg/kg) are identified for further study.

Conclusions:

• Neoadjuvant immunotherapy is a viable and effective treatment strategy for stage III melanoma.
• Pathologic response assessment is a critical tool for stratifying risk and predicting outcomes.
• Further investigation into optimal dosing and translational effects is warranted, with consideration for clinical trial enrollment.